Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
NCT: NCT06071845 · RECRUITING
Brief Summary
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minimally invasive, non-endoscopic, encapsulated sponge sampling device to identify BE/EAC biomarkers that indicate whether a patient should undergo diagnostic endoscopy. The OGE test is a simple and cost effective screening method that may lower barriers to widespread adoption of BE screening in at risk patients, resulting in increased and earlier detection of BE/EAC.
Frequently Asked Questions
What is Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples?
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples is a clinical trial registered under NCT06071845. Current status: RECRUITING.
What is the status of NCT06071845?
The current status of NCT06071845 (Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples) is: RECRUITING.
When did Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples start?
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples started on 2023-10-16.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.